Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 1/2 2

Status

Completed 4Terminated 1

Sponsor Class

OTHER 7INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 3Other hematologic neoplasm 2Lymphoid 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Recurrence 2Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × sonidegib × Clear all
NCT01327053 2019-08-28

BOLT

Novartis

Phase 2 Completed
230 enrolled 26 charts
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT01708174 2017-08-11

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Novartis

Phase 2 Completed
22 enrolled 12 charts
CNS

Medulloblastoma, Recurrence

NCT01826214 2016-08-30

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

Novartis

Phase 2 Completed
70 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02002689 2016-05-02

SIGNATURE

Novartis

Phase 2 Terminated
10 enrolled 9 charts
DermatologicGastrointestinalGynecologicOther hematologic neoplasm

Basal Cell Nevus Syndrome, Colonic Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT01350115 2015-10-19

Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Novartis

Phase 2 Completed
10 enrolled 9 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡